Chemo-Free hope: new drug combo may spare breast cancer patients toxic side effects
NCT ID NCT07432178
First seen Mar 17, 2026 · Last updated Jun 02, 2026 · Updated 10 times
Summary
This study tests if a targeted drug (dalpiciclib) combined with hormone therapy can replace chemotherapy for women with small but high-risk ER-positive breast cancer. About 2,288 participants will either receive the new drug combo or standard chemo followed by hormone therapy. The goal is to see if skipping chemo is just as effective at preventing cancer return while avoiding harsh side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.